SG11201810965YA - 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors - Google Patents
1h-pyrazolo[4,3-b]pyridines as pde1 inhibitorsInfo
- Publication number
- SG11201810965YA SG11201810965YA SG11201810965YA SG11201810965YA SG11201810965YA SG 11201810965Y A SG11201810965Y A SG 11201810965YA SG 11201810965Y A SG11201810965Y A SG 11201810965YA SG 11201810965Y A SG11201810965Y A SG 11201810965YA SG 11201810965Y A SG11201810965Y A SG 11201810965YA
- Authority
- SG
- Singapore
- Prior art keywords
- ottiliavej
- valby
- lundbeck
- international
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
WO 18/007 249 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) WIP0 I PCT il l 1E1 o 1 o 0111 OH 10 o I I 111010111 X10111110 lII o (10) International Publication Number WO 2018/007249 Al (51) International Patent Classification: C07D 471/04 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/EP2017/066255 (22) International Filing Date: 30 June 2017 (30.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA 2016 00397 04 July 2016 (04.07.2016) DK PA 2016 00612 11 October 2016 (11.10.2016) DK PA 2017 00236 04 April 2017 (04.04.2017) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventors: KEHLER, Jan; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JUHL, Karsten; c/o H. Lundbeck A/ S Ottiliavej 9, 2500 Valby (DK). MARIGO, Mauro; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). VITAL, Paulo, Jorge, Vieira; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JESSING, Mikkel; c/o H. Lundbeck A/ S Ottiliavej 9, 2500 Valby (DK). LANGGARD, Morten; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). RAS- MUSSEN, Lars, Kyhn; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). CLEMENTSON, Carl, Martin, Sebas- tian; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS (57) : The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and R4 N psychiatric disorders. IR2 (I) R1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600397 | 2016-07-04 | ||
| DKPA201600612 | 2016-10-11 | ||
| DKPA201700236 | 2017-04-04 | ||
| PCT/EP2017/066255 WO2018007249A1 (en) | 2016-07-04 | 2017-06-30 | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810965YA true SG11201810965YA (en) | 2019-01-30 |
Family
ID=60806291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810965YA SG11201810965YA (en) | 2016-07-04 | 2017-06-30 | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors |
Country Status (39)
| Country | Link |
|---|---|
| US (7) | US10034861B2 (en) |
| EP (2) | EP3478681B1 (en) |
| JP (1) | JP7096171B2 (en) |
| KR (2) | KR102488909B1 (en) |
| CN (1) | CN109311872B (en) |
| AU (1) | AU2017291794C1 (en) |
| CA (1) | CA3026857A1 (en) |
| CL (1) | CL2019000010A1 (en) |
| CO (1) | CO2018013803A2 (en) |
| CR (1) | CR20190003A (en) |
| CY (1) | CY1122957T1 (en) |
| DK (1) | DK3478681T3 (en) |
| DO (1) | DOP2018000266A (en) |
| EC (1) | ECSP18093944A (en) |
| ES (1) | ES2784655T3 (en) |
| GE (2) | GEAP202014955A (en) |
| HR (1) | HRP20200440T1 (en) |
| HU (1) | HUE048576T2 (en) |
| IL (1) | IL263511B (en) |
| JO (1) | JO3819B1 (en) |
| LT (1) | LT3478681T (en) |
| MA (1) | MA52593A (en) |
| ME (1) | ME03672B (en) |
| MX (1) | MX375782B (en) |
| MY (1) | MY197140A (en) |
| PE (1) | PE20190339A1 (en) |
| PH (1) | PH12018502604A1 (en) |
| PL (1) | PL3478681T3 (en) |
| PT (1) | PT3478681T (en) |
| RS (1) | RS60072B1 (en) |
| RU (1) | RU2759380C2 (en) |
| SG (1) | SG11201810965YA (en) |
| SI (1) | SI3478681T1 (en) |
| SM (1) | SMT202000148T1 (en) |
| SV (1) | SV2018005801A (en) |
| TW (1) | TWI763683B (en) |
| UA (1) | UA122824C2 (en) |
| WO (1) | WO2018007249A1 (en) |
| ZA (1) | ZA201808257B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) * | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (en) | 2016-12-22 | 2019-05-28 | H Lundbeck As | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| RU2020118913A (en) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | TYPES OF COMBINED TREATMENT INVOLVING THE INTRODUCTION OF 1H-PYRAZOLO[4,3-B]PYRIDINES |
| AR113926A1 (en) | 2017-12-14 | 2020-07-01 | H Lundbeck As | DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES |
| US10766893B2 (en) * | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JP7194738B2 (en) * | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors |
| TW201927784A (en) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | Macrocycles as PDE1 inhibitors |
| AU2019275453B2 (en) | 2018-05-25 | 2023-12-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR102907028B1 (en) | 2019-02-13 | 2026-01-05 | 피티씨 테라퓨틱스, 인크. | Thioeno[3,2-B]pyridin-7-amine compound for the treatment of familial dysautonomia |
| US12398140B2 (en) | 2019-02-13 | 2025-08-26 | Ptc Therapeutics, Inc. | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia |
| JP7706375B2 (en) | 2019-04-12 | 2025-07-11 | イントラ－セルラー・セラピーズ・インコーポレイテッド | organic compound |
| EP3982949A4 (en) * | 2019-06-14 | 2023-10-11 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| WO2021253180A1 (en) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators |
| CN112390750B (en) * | 2020-11-11 | 2022-03-01 | 常州大学 | Quinolinone compounds as selective phosphodiesterase 2 inhibitors and preparation method thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| DE19942474A1 (en) | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo [4,3-d] pyrimidines |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| RU2348633C2 (en) * | 2002-12-23 | 2009-03-10 | Глаксо Груп Лимитед | PYRASOLE[3,4-b]PYRIDINE COMPOUNDS AND THEIR APPLICATION AS PHOSPHODIESTERASE INHIBITORS |
| KR20070042164A (en) | 2004-07-05 | 2007-04-20 | 아스텔라스세이야쿠 가부시키가이샤 | Pyrazolopyridine derivatives |
| KR100710430B1 (en) * | 2004-08-24 | 2007-04-24 | 삼성코닝 주식회사 | Surface light source device and back light unit having same |
| ATE430746T1 (en) | 2004-10-19 | 2009-05-15 | Smithkline Beecham Cork Ltd | CRF RECEPTOR ANTAGONISTS AND ASSOCIATED METHODS |
| AU2006210392A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune response modifiers |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| RU2402549C3 (en) | 2005-04-14 | 2022-03-10 | Оцука Фармасьютикал Ко., Лтд. | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR THE TREATMENT OF MENTAL DISORDERS |
| BRPI0620239B8 (en) | 2005-12-22 | 2021-05-25 | Newron Pharm Spa | 2-phenylethylamino derivatives. |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| DK2124944T3 (en) * | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo [3,4-b] pyridine derivatives as phosphodiesterase inhibitors |
| BRPI0922700A2 (en) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Organic compounds |
| CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
| PT3042917T (en) | 2010-08-12 | 2018-05-02 | Lilly Co Eli | ANTI-N3PGLU BETA AMYLOID PEPTIDE ANTIBODIES AND ITS USES |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| CA2831680C (en) | 2011-04-21 | 2020-04-21 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| CN104024258B (en) * | 2011-09-01 | 2017-02-15 | 霍夫曼-拉罗奇有限公司 | Pyrrolopyrazine kinase inhibitors |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| TW201533043A (en) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors |
| SI3010503T1 (en) * | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
| UA116023C2 (en) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Ethynyl derivatives as metabotropic glutamate receptor antagonists |
| US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US20170066741A1 (en) | 2014-02-19 | 2017-03-09 | H. Lundbeck A/S | 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease |
| TWI599358B (en) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | Combination therapy |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| JP2017527606A (en) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Tricyclic derivatives |
| TW201629064A (en) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | Triazolopyrainones as PDE1 inhibitors |
| JO3458B1 (en) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2-Amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridine as BACE1 inhibitors |
| MA40941A (en) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS |
| CR20170187A (en) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease |
| TW201639851A (en) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | Bicyclic imidazolo derivative |
| TW201643167A (en) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | Imidazotriazinones as PDE1 inhibitors |
| JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| RU2018104868A (en) | 2015-08-12 | 2019-09-13 | Х. Лундбекк А/С | 2-amino-3-fluorine-3- (fluoromethyl) -6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
| WO2017100276A1 (en) | 2015-12-08 | 2017-06-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
| MX2018005767A (en) | 2015-12-09 | 2019-05-16 | Ford Global Tech Llc | Alert for left-behind mobile device. |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (en) | 2016-12-22 | 2019-05-28 | H Lundbeck As | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| RU2020118913A (en) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | TYPES OF COMBINED TREATMENT INVOLVING THE INTRODUCTION OF 1H-PYRAZOLO[4,3-B]PYRIDINES |
| AR113926A1 (en) | 2017-12-14 | 2020-07-01 | H Lundbeck As | DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES |
| JP7194738B2 (en) | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors |
| TW201927784A (en) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | Macrocycles as PDE1 inhibitors |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-06-29 US US15/637,920 patent/US10034861B2/en active Active
- 2017-06-30 EP EP17734307.6A patent/EP3478681B1/en active Active
- 2017-06-30 PE PE2018003262A patent/PE20190339A1/en unknown
- 2017-06-30 DK DK17734307.6T patent/DK3478681T3/en active
- 2017-06-30 MX MX2018015734A patent/MX375782B/en active IP Right Grant
- 2017-06-30 HU HUE17734307A patent/HUE048576T2/en unknown
- 2017-06-30 MA MA052593A patent/MA52593A/en unknown
- 2017-06-30 SG SG11201810965YA patent/SG11201810965YA/en unknown
- 2017-06-30 PT PT177343076T patent/PT3478681T/en unknown
- 2017-06-30 SM SM20200148T patent/SMT202000148T1/en unknown
- 2017-06-30 ES ES17734307T patent/ES2784655T3/en active Active
- 2017-06-30 GE GEAP202014955A patent/GEAP202014955A/en unknown
- 2017-06-30 EP EP20158664.1A patent/EP3689874A1/en not_active Withdrawn
- 2017-06-30 CR CR20190003A patent/CR20190003A/en unknown
- 2017-06-30 HR HRP20200440TT patent/HRP20200440T1/en unknown
- 2017-06-30 KR KR1020197000212A patent/KR102488909B1/en active Active
- 2017-06-30 RS RS20200308A patent/RS60072B1/en unknown
- 2017-06-30 GE GEAP201714955A patent/GEP20207172B/en unknown
- 2017-06-30 KR KR1020227039315A patent/KR102576888B1/en active Active
- 2017-06-30 UA UAA201812546A patent/UA122824C2/en unknown
- 2017-06-30 CN CN201780036674.9A patent/CN109311872B/en active Active
- 2017-06-30 WO PCT/EP2017/066255 patent/WO2018007249A1/en not_active Ceased
- 2017-06-30 CA CA3026857A patent/CA3026857A1/en active Pending
- 2017-06-30 ME MEP-2020-50A patent/ME03672B/en unknown
- 2017-06-30 SI SI201730204T patent/SI3478681T1/en unknown
- 2017-06-30 RU RU2018143324A patent/RU2759380C2/en active
- 2017-06-30 PL PL17734307T patent/PL3478681T3/en unknown
- 2017-06-30 MY MYPI2018002409A patent/MY197140A/en unknown
- 2017-06-30 AU AU2017291794A patent/AU2017291794C1/en not_active Ceased
- 2017-06-30 JP JP2018568885A patent/JP7096171B2/en active Active
- 2017-06-30 LT LTEP17734307.6T patent/LT3478681T/en unknown
- 2017-07-03 TW TW106122235A patent/TWI763683B/en not_active IP Right Cessation
-
2018
- 2018-07-12 US US16/033,395 patent/US10512632B2/en active Active
- 2018-12-05 IL IL263511A patent/IL263511B/en active IP Right Grant
- 2018-12-05 DO DO2018000266A patent/DOP2018000266A/en unknown
- 2018-12-06 ZA ZA2018/08257A patent/ZA201808257B/en unknown
- 2018-12-09 JO JOP/2018/0116A patent/JO3819B1/en active
- 2018-12-10 PH PH12018502604A patent/PH12018502604A1/en unknown
- 2018-12-14 SV SV2018005801A patent/SV2018005801A/en unknown
- 2018-12-19 CO CONC2018/0013803A patent/CO2018013803A2/en unknown
- 2018-12-19 EC ECSENADI201893944A patent/ECSP18093944A/en unknown
-
2019
- 2019-01-03 CL CL2019000010A patent/CL2019000010A1/en unknown
- 2019-10-31 US US16/670,408 patent/US10806718B2/en active Active
-
2020
- 2020-03-20 CY CY20201100264T patent/CY1122957T1/en unknown
- 2020-07-30 US US16/943,496 patent/US11491140B2/en active Active
- 2020-08-21 US US16/999,247 patent/US20200375950A1/en not_active Abandoned
- 2020-10-01 US US17/060,742 patent/US11026923B2/en active Active
- 2020-10-01 US US17/060,796 patent/US11026924B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201809630RA (en) | Nicotine particles | |
| SG11201908159QA (en) | Dual magl and faah inhibitors |